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Abstract 
Background: To summarise the evidence on the associations between body mass index 
(BMI) and BMI in early adulthood, height, waist circumference (WC) and waist to hip ratio 
(WHR), and risk of lympho-hematopoietic cancers. 
Method: We conducted a meta-analysis of prospective studies and identified relevant studies 
published up to December 2017 by searching PubMed. A random effects model was used to 
calculate dose-response summary relative risks (RRs). 
Results: Our findings showed BMI, and BMI in early adulthood (aged 18-21 years) is 
associated with the risk of Hodgkin’s and Non-Hodgkin’s lymphoma (HL and NHL), Diffuse 
Large Beta Cell Lymphoma (DLBCL), Leukaemia including Acute and Chronic Myeloid 
Lymphoma (AML and CML), and Chronic Lymphocytic Leukaemia (CLL) and Multiple 
Myeloma. The summary RR per 5 kg/m² increase in BMI were 1.12 (95% CI: 1.05-1.20) for 
HL, 1.05 (95% CI:1.03-1.08) for NHL, 1.11 (95% CI:1.05-1.16) for DLBCL, 1.06 (95% 
CI:1.03-1.09) for ML, 1.09 (95% CI:1.03-1.15) for leukaemia, 1.13 (95% CI:1.04-1.24) for 
AML, 1.13 (95% CI:1.05-1.22) for CML and 1.04 (95% CI:1.00-1.09) for CLL, and 
were1.12 (95% CI:1.05-1.19) for NHL, 1.22 (95% CI:1.09-1.37) for DLBCL, and 1.19 (95% 
CI:1.03-1.38) for FL for BMI in early adulthood analysis.Results on mortality showed a 15%, 
16% and 17% increased risk of NHL, multiple myeloma and leukaemia, respectively. Greater 
height increased the risk of NHL by 7%, DLBCL by 10%, FL by 9%, multiple myeloma by 
5%, and Leukaemia by 7%. WHR was associated with increased risk of DLBCL by 12%. No 
association was found between higher WC and risk of multiple myeloma.  
Conclusion 
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Our results revealed that general adiposity in adulthood and early adulthood, and greater 
height may increase the risk of almost all types of lympho-hematopoietic cancers and this 
adds to a growing body of evidence linking body fatness to several types of cancers. 
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Introduction 
Overweight and obesity are a global health problem. During the last forty years, the number 
of obese adults increased from 100 million in 1975 (69 million women, 31 million men) to 
671 million in 2016 (390 million women, 281 million men) [1]. Excess weight and obesity 
have been linked to several chronic diseases including cardiovascular disease [2,3], diabetes 
[3] and many types of cancersincluding lympho-hematopoietic cancers [4]. 
The age standardized incidence rates worldwide (per 100 000 inhabitants) were estimated of 
1.0 for HL, 6.7 for NHL, 2.1 for multiple myeloma and 5.7 for leukaemia in 2018 [5]. 
Although, lympho-hematopoietic cancers are not as frequent as other cancers such as lung, 
breast, colorectal and prostate cancers, it is very important to investigate their association 
with overweight and obesity, which are the major public health issues. Consequentlyfindings 
can add to the existing literature about the importance of lifestyle modification specifically 
weight management in prevention of haematological cancer incidence and mortality     
[4]. 
Previous meta-analyses published up to 2014, showed that greater BMI may increase the  risk 
of HL [6], NHL [6], DLBCL [7], myeloma [8] and leukaemia [9]. Since the publication of 
these meta-analysis, several additional large prospective studies with large number of cases 
have been published [10-16]. The accumulated evidence has greatly enhanced the 
investigation of how these modifiable risk factors influence the development of the many 
different types of lympho-haematopoietic cancers. Moreover, whether BMI in early 
adulthood (age 18-21 years), height, and abdominal obesity increase the risk of lympho-
haematopoietic cancers, has not been summarized in a meta-analysis. Therefore, we 
conducted a systematic literature review and meta-analysis of prospective studies of BMI, 
BMI in early adulthood, height, weight, waist circumference and waist to hip ratio, and the 
risk of lymphoma, myeloma and leukaemia, and their main types to provide an up-to-date and 
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comprehensive assessment of the existing evidence. We aimed to clarify the strength and 
shape of dose-response relationship between the general and abdominal adiposity and 
lympho-haematopoietic cancers and investigate any potential differences by sub-sites, sex, 
geographical locations, size of cohort, number of cases, years of follow up, exposure 
assessment methods, and adjustment for potential confounders. 
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Methods 
Search strategy and inclusion criteria 
The CUP team at Imperial College London searched in PubMed for studies on 
anthropometric measures including BMI, BMI in early adulthood (age 18-21), height, weight, 
waist circumference and waist to hip ratio, and lympho-hematopoietic cancer risk up to 
December 2017. The specific search criteria and the review protocol can be seen in 
supplementary materials. 
Study selection 
Our study selection was restricted to cohort (prospective, retrospective, case–cohort or nested 
case–control studies) studies which investigated the link between anthropometric measures 
and lympho-hematopoietic cancer risk and mortality, and reported estimates of the relative 
risk (RR) (e.g., hazard ratio, risk ratio or odds ratio) and 95% confidence intervals (CIs) for 
the exposures of interest (BMI, BMI in early adulthood (aged 18-21 years), weight, waist 
circumference, and waist-to-hip ratio). In case of studies reporting only categorical results, 
number of cases and denominator data (person-years of follow-up or number of subjects) 
were required for inclusion in the meta-analysis. If there were multiple publications from the 
same study, the newest publication which included the largest number of cases was selected.  
Data extraction 
We extracted the following data from each study: authors, year of publication, country of 
origin, cancer type, length of study and loss of follow up, sample size, numbers of cases and 
population at risk/controls, age, sex and other characteristics, anthropometric measures, 
relative risks and 95% confidence intervals or P-values for each exposure category and 
adjustment variables. A second reviewer checked at least 10% of the work.  
Statistical analysis 
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We calculated the summary RRs and 95% CIs using random effect models which takes into 
account heterogeneity between studies[17]. Q and I² statistics were used to determine 
heterogeneity [18], potential sources of which were explored in stratified analyses by sex, 
geographical location, exposure assessment methods, years of follow-up, number of cases, 
size of cohort, and adjustments for confounders including alcohol consumption, smoking, and 
physical activity. 
We used RR estimates and CIs for continuous increments directly from the articles if 
provided, and for studies that only reported categorical data,  dose-response associations and 
95% CIs were derived using generalized least-squares for trend estimation [19], which 
required the RRs and CIs associated to at least three categories of anthropometric measures, 
and number of cases and non-cases or person years of follow up per category to be available.  
If only the total number of cases or person years was reported in the articles, and the exposure 
was categorised in quantiles, the distribution of persons or person years was calculated by 
dividing the total number of persons or person years by the number of quantiles. We used the 
mean or median values per each anthropometric category if available in the articles, or the 
midpoint was calculated for studies that only reported a range by category. If the range of the 
highest or lowest category was open-ended, its width was assumed to be the same as the 
adjacent category. In case of close-ended lowest and highest categories with category widths 
substantially greater than those of the middle-categories (e.g. highest category of 35-60 
kg/m
2
of BMI), the Chêne and Thompson [20] method was used to estimate the midpoints. 
The Hamling’s method was used to recalculate the relative risk estimates when the first 
category was not used as reference [19]. If the results were reported for men and women 
separately, they were combined using a fixed effects meta-analysis before being pooled with 
other studies in linear, but not non-linear, analyses. 
We assessed small-study effects, such as publication bias, by using funnel plots and Egger’s 
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test [21]. 
We assessed a potential nonlinear dose-response association between anthropometric 
measures and risk of lympho-hematopoietic cancers when we had ≥ 3 studies by calculating 
restricted cubic splines for each study, using three fixed knots at 10
th
, 50
th
, and 90
th
 
percentiles of distribution of the exposure to account for a wider exposure range while 
minimising any potential impact from the outliers in the tails, and combined them by using 
multivariate meta-analysis. In order to be eligible for this procedure, at least three categories 
of exposure needed to be reported by a given study. 
For all analyses, the results of each article with the most comprehensive adjustment for 
confounders were included. A two-tailed p<0.05 was considered statistically significant. 
Stata version 13.1software (StataCorp, College Station, TX) was used. 
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Results 
Study selection is shown in the flowchart (Figure 1). 
Out of 65 publications, 27 studies (37 publications[10-15,22-52]) on blood cancers risk 
(lymphoma, leukaemia and myeloma) and 68 studies (10 publications including 1 Pooled 
analysis of 39 cohorts and 1 Pooled analysis of 20 cohort studies[22,46,46,50-
53,53,54,54,55,55,56,56,57,57])on blood cancers mortality (lymphoma, leukaemia and 
myeloma) were included in the dose-response meta-analyses. The characteristics of the 
included studies are shown in supplementary materials. 
BMI and lymphomas risk and mortality 
The summary RR per 5 kg/m
2 
increase of BMI was 1.12 (95%CI=1.05-1.20, I
2
=1.9%, 
Pheterogeneity =0.40) for HL (5 studies[12,36,39,40,58], Figure 2A), 1.05(95%CI: 1.03-1.08, 
I
2
=45%, Pheterogeneity =0.02) for NHL (20 studies[10-12,23,24,27-31,33,34,36,39-42,58], 
Figure 3), 1.11, 95%CI=1.05-1.16, I
2
=16%, Pheterogeneity =0.29) for DLBCL (18 
studies[11,12,24,26,29,30,32,33,36,42,48], supplementary Figure 1), and 1.03 (95%CI=0.98-
1.09, I
2
=3%, Pheterogeneity =0.41) for FL (19 studies [11,12,24,26,29,30,32,33,36,42,48], 
supplementary Figure 2).  
The summary RR per 5 kg/m
2 
increase of BMI for NHL mortalitywas1.15 (95%CI=1.10-
1.20, I
2
=0%, Pheterogeneity =0.44, 6 studies [22,45,51,52,56,57]) (Table 1and supplementary 
Figure 3). 
There was no evidence of publication bias in any of the analysis (p-value for Egger’s test= 
0.24 for HL; 0.12 for NHL (incidence); 0.10 for NHL (mortality) 0.17 for DLBCL;0.37 for 
FL). 
There was evidence of nonlinearity of the association of BMI and HL (p for non-linearity < 
0.001). The risk increase was observed in the range of BMI above 32 kg/m
2 
(Figure 2B). 
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However, there was no evidence of non-linearity association between BMI and NHL (p for 
non-linearity=0.66) (Supplementary Figure 4), DLBCL (p for non-linearity=0.50) 
(Supplementary Figure 5), and FL (p for non-linearity=0.58) (Supplementary Figure 6). 
Moreover, there was no evidence of nonlinearity (p for non-linearity=0.66) between BMI and 
NHL mortality (Supplementary Figure 7). 
BMI and multiple myeloma (MM) risk and mortality 
The summary RR per 5 kg/m
2
 increment of BMI was 1.06 (95%CI=1.03-1.10, I
2
=13%, 
Pheterogeneity =0.31, 23 studies [10,12,14,15,26,27,30-32,37,40,43,44,59,60]) for MM risk 
(Figure 4) and 1.16 (95%CI=1.07-1.25, I
2
=20%, Pheterogeneity =0.27, 57 studies) for MM 
mortality (Table 1 and supplementary Figure 8). 
There was evidence of publication bias in MM risk analysis (the p-value for Egger’s test 
=0.05) but no evidence of publication bias in MM mortality analysis (p-value for Egger’s test 
= 0.26).  
There was no evidence of nonlinearity for the association of BMI and MM risk (p for non-
linearity=0.50) (Supplementary Figure 9), and mortality (p for non-linearity=0.33) 
(Supplementary Figure 10). 
BMI and leukaemia risk and mortality 
The summary RR per 5 kg/m
2
 increment of BMI was 1.09 (95%CI=1.03-1.15, I
2
=46%, 
Pheterogeneity =0.05, 12 studies [10,12,13,27,31,34,39,40,47,59,61]) for leukaemia, 
1.11(95%CI=1.03-1.21, I
2
=43%, Pheterogeneity =0.10, 14 studies[12,13,31,47,58,60]) for AML,  
1.13 (95%CI=1.05-1.22, I
2
=0%, Pheterogeneity =0.57, 4 studies[13,16,58,60]) for CML, and 1.04 
(95%CI=1.00-1.09, I
2
=0%, Pheterogeneity =0.65, 7 studies[13,30,31,39,47,58]) ) for CLL (Figure 
5).  
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The summary RR per 5 kg/m
2
 increment of BMI was 1.17 (95%CI=1.05-1.30, I
2
=49%, 
Pheterogeneity =0.06, 46 studies [45,46,51,52,54,56,57,62] for leukaemia mortality 
(Supplementary Figure 11).  
There was no evidence of publication bias in any of the analyses (p-value for Egger’s test 
=0.97 for leukaemia; 0.24 for AML; 0.68 for CML; 0.36 for CLL). 
There was no statistical evidence of departure from linearity (p-values for non-linearity tests 
were 0.60 for leukaemia risk; 0.46 leukaemia mortality; 0.68 for AML and 0.32 for CLL 
(Supplementary Figures 12, 13, 14 and 15, respectively). 
BMI in early adulthood (age 18-21 years) and lymphoma risk 
The summary RR per 5 kg/m
2 
increment of BMI was 1.12 (95%CI=1.05-1.19, I
2
=43%, 
Pheterogeneity =0.10) for NHL (7 studies [11,23,24,29,33,42]) (Table 1 and supplementary 
Figure 16), 1.22 (95%CI=1.09-1.37, I
2
=0%, Pheterogeneity =0.77) for DLBCL(8 studies 
[11,24,29,30,33,42,48]) (Table 1 and supplementary Figure 17), and 1.19 (95%CI=1.03-1.38, 
I
2
=2%, Pheterogeneity =0.41) for FL (8 studies [11,24,29,30,33,42,48]) (Table 1 and 
supplementary Figure 18). 
There was no evidence of publication bias in most of the analyses (p-value for Egger’s test 
=0.36 for NHL; 0.74 for DLBCL). However, there was an evidence of publication bias in the 
FL analysis (p-value for Egger’s test =0.05). Visual inspection of the funnel plot showed 
moderate asymmetry, which appeared to be driven by the strong and relatively precise 
association reported in the NHS study [11]. 
There was some evidence of nonlinearity of the association of early adulthood BMI and NHL 
(p for non-linearity=0.05), with steady risk increase within the BMI range of approximately 
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15-23 kg/m
2
, with gradual flattening of the slope with increasing BMI thereafter 
(Supplementary Figure 19). 
There was no evidence of nonlinearity of the association of early adulthood BMI and DLBCL 
(p for non-linearity=0.83) (Supplementary Figure 20), and FL (p for non-linearity=0.60) 
(Supplementary Figure 21). 
Height 
Height and lymphoma risk 
The summary RR per per 5 cm increment of height was 1.07 (95%CI=1.05-1.10, I
2
=70%, 
Pheterogeneity<0.01) for NHL(13 studies[11,12,23-25,28-30,33,42,58,63]) (Table 1 and 
supplementary Figure 22), 1.10 (95%CI=1.06-1.15, I
2
=41%, Pheterogeneity 0.09) for DLBCL (10 
studies[11,12,24,29,30,32,33,36,42,48]) (Table 1 and supplementary Figure 23), and 1.09 
(95%CI=1.06-1.13, I
2
=0%, Pheterogeneity =0.54) for FL(10 studies[11,12,24,29,30,33,36,42,48]) 
(Table 1 and supplementary Figure 24). 
There was no evidence of publication bias in any of analysis (p-value for Egger’s test= 0.57 
for NHL; 0.48 for DLBCL; 0.64 for FL). 
There was no evidence of nonlinearity of the association between height and NHL (p for non-
linearity=0.51) (Supplementary Figure 25), DLBCL (p for non-linearity=0.98) 
(Supplementary Figure 26), and FL (p for non-linearity=0.29) (Supplementary Figure 27). 
Height and multiple myeloma risk 
The summary RR per per 5 cm increment of height was 1.05 (95%CI=1.02-1.08, I
2
=1%, 
Pheterogeneity=0.42, 8 studies [12,15,25,30,32,43,63,64]) (Table 1 and supplementary Figure 
28).There was no evidence of publication bias (p-value for Egger’s test= 0.64). 
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There was no evidence of nonlinearity of the association of height and MM (p for non-
linearity=0.17) (Supplementary Figure 29). 
Height and leukaemia risk 
The summary RR per per 5 cm increment of height was 1.07 (95%CI=1.03-1.11, I
2
=51%, 
Pheterogeneity =0.06, 7 studies [12,13,25,47,63-65]) (Table 1 and supplementary Figure 30). 
There was no evidence of publication bias (p-value for Egger’s test= 0.24). 
There was no evidence of nonlinearity of the association of height and Leukaemia (p for non-
linearity=0.76) (Supplementary Figure 31). 
Weight 
Weight and lymphoma risk 
The summary RR per 5 kg increment of weight was 1.02 (95%CI=0.99-1.06, I
2
=70%, 
Pheterogeneity=0.01) for NHL (5 studies[24,28,29,33,42]) (Supplementary Figure 32), 1.03 
(95%CI=0.98-1.07, I
2
=22%, Pheterogeneity=0.89) for DLBCL (6 studies [24,29,32,33,42,48]) 
(Supplementary Figure 33), and 1.00 (95%CI=0.96-1.04, I
2
=7%, Pheterogeneity =0.37) for FL (6 
studies [24,29,32,33,42,48]) (Supplementary Figure 34) (Table 1). 
There was no evidence of publication bias (the p-value for Egger’s test= 0.56 for NHL; 0.89 
for DLBCL; 0.40 for FL). 
There was no evidence of nonlinearity of the association of weight and NHL (p for non-
linearity=0.35) (Supplementary Figure 35), DLBCL (p for non-linearity=0.81) 
(Supplementary Figure 34), and FL (p for non-linearity=0.45) (Supplementary Figure 37). 
Waist circumference 
Waist circumference and lymphoma risk 
14 
 
The summary RR per 5 cm increment of waist circumference was 1.06 (95%CI=0.97-1.15, 
I
2
=0%, Pheterogeneity=0.92, 5 studies [11,24,32,48]) for DLBCL and 1.00 (95%CI=0.92-1.09, 
I
2
=0%, Pheterogeneity=0.80, 5 studies [11,24,32,48]) for FL (Supplementary Figure 38 and 39). 
There were not enough studies to conduct the non-linear analysis.  
Waist circumference and multiple myeloma risk 
The summary RR per 5 cm increment of waist circumference was 1.01 (95%CI=0.97-1.05, 
I
2
=79.8%, Pheterogeneity<0.001, three studies [32,43,48]) (Table 1 and supplementary Figure 
40).  
There were not enough studies to conduct the non-linear analysis.  
Waist to hip ratio 
Waist to hip ratio and lymphoma risk 
The summary RR per 0.1 unit increment of waist to hip ratio was 1.12 (95%CI=1.01-1.26, 
I
2
=0%, Pheterogeneity =0.71) for DLBCL (7 studies [11,24,32,36,42,48]) (Supplementary Figure 
41), and 0.98 (95%CI=0.86-1.11, I
2
=0%, Pheterogeneity =0.84) for FL (7 studies 
[11,24,32,36,42,48]) (Supplementary Figure 42) (Table1). 
There was no evidence of publication bias in any of analysis (the p-value for Egger’s test= 
0.61 for DLBCL; 0.17 for FL). 
There was no evidence of nonlinearity of the association of WHR and DLBCL (p for non-
linearity = 0.45) (Supplementary Figure 43), and FL (p for non-linearity = 0.75) 
(Supplementary Figure 44). 
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Subgroup analyses 
The observed associations in the main analysis persisted in most subgroup analyses defined 
by sex, geographical locations, exposure assessment methods, duration of follow-up, cohort 
size, number of cases and adjustments for potential confounding factors including alcohol 
consumption, smoking and physical activity, although the results were not always statistically 
significant (Table 1 and Supplementary tables). There were no apparent differences between 
the subgroups that could explain the moderate heterogeneity observed in the analyses of BMI 
and risk of NHL and AML and leukaemia mortality; BMI in early adulthood and NHL; and 
height and NHL. For the analysis of BMI and leukaemia, weaker positive associations were 
observed in the studies in men than studies in women. For the analyses of height and DLBCL 
and leukaemia, null associations were observed in the studies in men, which were also studies 
with medium-size of cohort and >20 years of follow-up. Other factors did not appear to 
explain the observed heterogeneity.    
Study quality 
In most of the included studies, cases were ascertained via record linkage to cancer and death 
registries. All the studies were adjusted at least for age and sex, but only some studies were 
adjusted for confounders including alcohol consumption, smoking and physical activity; and 
unadjusted studies more often showed statistically significant results on average than adjusted 
studies. Most of the included studies used self-reported measurements. 
Most of the included studies did not report loss to follow up and only few studies reported a 
follow-up that was almost complete (≤1%) which include 5 studies for BMI [24,28,43,58,61], 
and height [24,25,28,43,58], 2 studies for weight [24,28], and 1 study [24] for BMI in early 
adulthood, waist to hip ratio and waist circumference. 
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Discussion 
This study provides the most comprehensive and up-to-date summary estimates of the 
association between all anthropometry factors including BMI, BMI in early adulthood, 
height, weight, waist circumference and waist to hip ratio and risk of lympho-hematopoietic 
cancers including lymphomas, multiple myeloma, and leukaemia. 
Higher BMI showed to be associated with increased risk of all included type of lympho-
hematopoietic cancers, except for FL, for which no significant association was observed. The 
observed increased risk ranged from 4% in CLL to 13% in AML and CML, respectively, per 
5 kg/m
2
. Moreover, higher BMI in early adulthood (age 18-21) showed to increase the risk of 
NHL, FL and DLBCL cancers by 12%, 19% and 22%, respectively.  
Our main findings on BMI, are consistent with previous published meta-analysis which all 
showed greater BMI is associated with increased risk of HL [6], NHL [6], DLBCL [7], 
multiple myeloma [8] and leukaemia [9]. However, our meta-analysis included higher 
number of studies and we did separate analysis for BMI in early adulthood. We also 
investigated the associations by subgroup analyses, including sex, geographical locations, 
size of cohort, number of cases, years of follow up, exposure assessment methods, and 
adjustment for potential confounders for all types of lympho-hematopoietic cancers, 
providing a more comprehensive estimate of the effects of adiposity in the incidence of 
lympho-hematopoietic cancers. 
The analysis on height also revealed that greater height was associated with increased risk of 
lymphomas, multiple myeloma and leukaemia, and the increased risks ranged from  
5%  in multiple myeloma to 10% in DLBCL, respectively.  
Our results on abdominal obesity and the risk of lympho-hematopoietic cancers using WHR 
and waist circumference measures showed an increased risk of DLBCL by12% with higher 
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WHR, and no association was found between higher waist circumferences and risk of 
multiple myeloma which could be due to limited number of studies (n=3). 
Several risk factors of haematological malignancies have been identified including radiation, 
chemicals (e.g. benzene for AML [66]), viruses (e.g. Epstein Barr virus for adult HL [67]), 
HIV infection[68], hepatitis C virus for NHL [69] and some conditions such as autoimmune 
disease and chronic inflammatory conditions [7,9]. However, less is known about lifestyle 
factors. There are several potential mechanisms whereby excess body fatness may increase 
the risk of haematological malignancies [70,71]. Body fatness and obesity leads to changes in 
circulating levels of adipocytokines, including adiponectin, resistin, and leptin, and these 
hormones can affect insulin resistance, immunity, and inflammation[7,70-75]. Leptin has pro-
inflammatory properties and promotes the growth of some cancer cells, and it stimulates the 
proliferation of normal haematopoietic cells and circulating monocytes producing pro-
inflammatory cytokines [71,75]. Also, obesity may increase the risk of lymphoma by 
affecting insulin resistance and hyper-insulinemia which leads to increased bio-available 
insulin-like growth factor-I (IGF-I)[71]. IGF-I is known to act as a growth factor which 
promotes cell proliferation and inhibits apoptosis through IGF-I receptor-mediated signalling 
mechanisms in various tissues, including haematopoietic cells [71]. 
Our meta-analysis has some limitations that should be taken into account when interpreting 
the results. Moderate proportions of between-study heterogeneity were observed in some 
analyses and remained largely unexplained by the factors explored in the current study. In 
some subgroup analyses, the number of studies was too small to allow full exploration of 
heterogeneity. Uncontrolled confounding maybe an issue, particularly for BMI and AML, 
where smoking which is linked to body weight [76] has been shown to increase the risk of 
AML [77] 
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It is possible that our results could be biased due to the fact that most of studies used self-
reported BMI rather than measured, and there is an observed tendency for overweight and 
obese people to overestimate height and underestimate weight compared to normal weight 
individuals. However, when we analysed the data according to measured or self-reported 
anthropometry the results were mostly similar, with confidence intervals overlapping.  
Another limitation of the study is that not all studies separated the haematopoietic cancers 
according to the current WHO classification system. For instance, the most current lymphoid 
malignancy classification system typically considers CLL to be the same cancer as SLL and 
as such, CLL/SLL is considered as non-Hodgkin lymphoma. Some of the studies included in 
the meta-analysis for NHL include CLL and others may also include multiple myeloma. This 
potential source of heterogeneity could not be addressed. Also, there may be an overlapping 
of some cancers across groups. 
A strength of our study are as follows:(i) inclusion of large studies with prospective design, 
which reduces the possibility of recall or selection bias (ii) large number of studies with 
relatively long duration of follow up and large number of cases that increase the statistical 
power of our analysis, and (iii) the nonlinear analyses which allowed us to examine the shape 
of the dose–response relationships.  
Conclusion 
In conclusion, our results revealed that greater BMI in adulthood as well as greater height 
may increase the risk of lympho-hematopoietic cancers and this adds to a growing body of 
evidence linking body fatness to several types of cancers. 
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Table 1. Summary of results 
  BMI, per 5 kg/m²  BMI in early adulthood (age 18-21 yrs), per 5 kg/m² 
 n Cases RR (95% CI) I
2
 (%) Ph
 
   n Cases RR (95% CI) I
2
 (%) Ph
 
Incidence 
 
Hodgkin’s Lymphoma 
 
        
All studies 5 1 776 1.12 (1.05-1.20) 1.9%,  0.40      
Stratified by 
sex 
          
   Men 2 932 1.00 (0.90-1.10) 0%,  0.34      
   Women 2 756 1.23 (1.13-1.34) 0%,  0.49      
Stratified by geographic location 
   Europe 3 1688 1.14 (1.02-1.27) 47.9%,  0.15      
North America 1 57 1.08 (0.74-1.57) - -      
   Asia 1 31 1.31(0.66-2.63) - -      
           
Non-Hodgkin’s Lymphoma 
 
 
       
All studies 20 30 898 1.05 (1.03-1.08) 45%,  0.02 7 6 211 1.12 (1.05-1.19) 43% 0.10 
Stratified by 
sex 
          
   Men 7 7 910 1.06 (1.02-1.09) 0%,  0.64 3 2 052 1.09 (0.95-1.27) 76% 0.01 
   Women 10 12 287 1.04 (1.00-1.09) 62%,  <0.01 5 2 990 1.13 (1.05-1.21) 0% 0.73 
Stratified by geographic location 
   Europe 7 21 413 1.05 (1.01-1.09) 55%,  0.04      
North America 9 8 940 1.05 (1.01-1.10) 54%,  0.02 7 6 211 1.12 (1.05-1.20) 43% 0.10 
   Asia 3 545 1.13 (0.97-1.31) 0%,  0.67      
           
Diffuse Large Beta Cell Lymphoma 
 
       
All studies 19 3 109 1.11(1.05-1.16) 16% 0.29 8 1 315 1.22 (1.09-1.37) 0% 0.77 
Stratified by 
sex 
          
   Men 10 410 1.12 (0.93-1.33) 21.7% 0.28 2 211 1.09 (0.78-1.52) 36% 0.21 
21 
 
   Women 13 2 082 1.12 (1.07-1.18) 0% 0.61 5 730 1.28 (1.08-1.51) 0% 0.83 
Stratified by geographic location 
   Europe 10 1 634 1.13 (1.01-1.26) 43% 0.15 1 182 1.26 (0.97-1.62)   
North America 8 1 653 1.08 (1.02-1.15) 0% 0.55 7 1 133 1.21 (1.07-1.38) 0% 0.68 
   Asia           
Follicular Lymphoma 
 
       
All studies 19 2 546 1.03 (0.98-1.09) 3% 0.41 8 858 1.19 (1.03-1.38) 2% 0.41 
Stratified by 
sex 
          
   Men 10 252 1.19 (0.70-2.00) 79.8% <0.01 2 113 1.11 (0.73-1.68) 0% 0.40 
   Women 13 1 799 1.03 (0.97-1.09) 0% 0.87 5 528 1.33 (1.11-1.58) 0% 0.60 
Stratified by geographic location 
   Europe 10 1 325 0.97 (0.91-1.05) 0% 0.44 1 67 0.96 (0.60-1.53)   
North America 8 1 221 1.08 (1.01-1.16) 0% 0.74 7 791 1.22 (1.04-1.43) 3% 0.40 
   Asia           
Multiple Myeloma 
 
       
All studies 23 7 807 1.06 (1.03-1.10) 13% 0.31      
Stratified by 
sex 
          
   Men 13 1 718 1.08 (1.00-1.17) 18.7% 0.29      
   Women 15 2 600 1.06 (1.02-1.11) 0% 0.46      
Stratified by geographic location 
   Europe 13 6 175 1.06 (1.02-1.10) 8% 0.37      
North America 7 1 531 1.06 (0.98-1.16) 30.6% 0.18      
   Asia 1 101 1.24 (0.77-2.02)        
           
Leukaemia 
 
          
All studies 12 10 054        1.09 (1.03-1.15) 46% 0.05      
Stratified by sex        
   Men 4 1 253 1.01 (0.90-1.14)  25.5%,  0.26      
   Women 6 2 493 1.14 (1.04-1.25) 47.7%,  0.09      
Stratified by geographic location 
   Europe 7 9 275 1.08 (1.02-1.14) 48.6%,  0.08      
North America 3 488 1.10 (0.94-1.29) 51.2%,  0.13      
   Asia 2 291 1.27 (0.89-1.82) 64.8%,  0.09      
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Acute Myeloid Leukaemia 
 
       
All studies 7 3 679 1.13 (1.04-1.24) 48%,  0.09      
Stratified by sex        
   Men 3 1 665 1.07 (1.00-1.15) 0%,  0.75
 
     
   Women 4 1 948 1.16 (1.03-1.32) 64.6%,  0.04      
Stratified by 
geographic 
location 
          
   Europe 6 3 607 1.10 (1.03-1.18) 23.6%,  0.26      
North America 1 72 1.49 (1.12-1.98) - -      
   Asia -  - - -      
           
Chronic Myeloid Leukaemia 
 
       
All studies 4 1 252 1.13 (1.05-1.22) 0%,  0.57      
Stratified by sex        
   Men 3 625 1.12 (0.97-1.29) 14%,  0.31      
   Women 2 449 1.11 (0.99-1.24) 0%,  0.93      
Stratified by 
geographic 
location 
          
   Europe 3 1 074 1.12 (1.04-1.22) 0%,  0.44      
North America 1 178 1.21 (0.98-1.50) - -      
   Asia -  - - -      
           
Chronic Lymphocytic Leukaemia 
 
       
All studies 7 3 820 1.04 (1.00-1.09) 0%,  0.65      
Stratified by 
sex 
          
   Men 3 2 196 1.04 (0.97-1.11) 7.7%,  0.34      
   Women 3 1 331 1.06 (1.00-1.13) 0%,  0.85      
Stratified by geographic location 
   Europe 6 3 736 1.04 (1.00-1.09) 0%,  0.54      
North America 1 84 1.12 (0.84-1.48) - -      
   Asia -  - - -      
           
Height per 5 cm   Weight per 5 kg   
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Non-Hodgkin’s Lymphoma 
 
       
All studies 13 23 771 1.07 (1.05-1.10) 70% <0.01 5 3 658 1.02 (0.99-1.06) 70% 0.01 
Stratified by sex        
   Men 5 8 493 1.06 (1.01-1.10) 88% <0.01 1 460 1.01 (0.95-1.06)   
   Women 9 13 194 1.08 (1.06-1.09) 0% 0.65 3 1 755 1.00 (0.98-1.02) 0% 0.65 
Stratified by geographic location 
   Europe 3 13 194 1.09 (1.06-1.12) 58% 0.09      
North America 9 10 389 1.06 (1.03-1.09) 62% <0.01 4 3 470 1.02 (0.98-1.06) 76.3% <0.01 
   Asia      1  1.06 (0.97-1.16)   
           
Diffuse Large Beta Cell Lymphoma 
 
       
All studies 11 3 202 1.10 (1.06-1.15) 41% 0.09 6 1 225 1.03 (0.98-1.07) 22% 0.89 
Stratified by 
sex 
          
   Men 3 308 0.99 (0.93-1.05) 0% 0.82 2 222 0.97 (0.89-1.06) 0% 0.97
 
   Women 7 2 112 1.13 (1.08-1.17) 0% 0.95 5 789 1.03 (0.98-1.07) 15.7% 0.31 
Stratified by geographic location 
   Europe 3 1 499 1.13 (1.07-1.20) 18% 0.30 1  1.06 (0.95-1.17)   
North America 8 1 703 1.09 (1.03-1.15) 40% 0.13 5 1 081 1.03 (0.99-1.07) 36.1% 0.18 
   Asia           
           
Follicular Lymphoma 
 
       
All studies 11 2 443 1.09 (1.06-1.13) 0% 0.54 6 841 1.00 (0.96-1.04) 7% 0.37 
Stratified by 
sex 
          
   Men 3 176 1.13 (0.96-1.34) 45% 0.16 2 104 1.06 (0.91-1.24) 21.4% 0.26 
   Women 7 1 771 1.12 (1.06-1.18) 9% 0.36 5 575 0.98 (0.91-1.06) 50.5% 0.09 
Stratified by geographic location 
   Europe 3 1 213 1.13 (1.07-1.20) 0% 0.99 1  0.95 (0.85-1.07)   
North America 8 1 230 1.07 (1.02-1.11) 0% 0.52 5 710 1.01 (0.96-1.05) 14% 0.32 
   Asia           
           
Multiple Myeloma 
 
       
All studies 8 3 597 1.05 (1.02-1.08) 1% 0.42      
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Stratified by sex       
   Men 2 713 1.03 (0.98-1.08) 0% 0.33      
   Women 7 2 605 1.08 (1.01-1.14) 41% 0.11      
Stratified by geographic location 
   Europe 3 2 075 1.06 (1.01-1.10) 0% 0.79      
North America 5 1 481 1.06 (0.99-1.13) 38% 0.17      
   Asia           
           
Leukaemia 
 
          
All studies 7 5 177 1.07 (1.03-1.11) 51.2% 0.06      
Stratified by sex        
   Men 3 1 778 1.02 (0.99-1.06) 0% 0.77      
   Women 7 3 399 1.10 (1.06-1.13) 13% 0.33      
Stratified by geographic location 
   Europe 2 2 441 1.10 (1.05-1.16) 22% 0.26      
North America 4 2 194 1.05 (1.00-1.10) 29% 0.24      
   Asia           
 Waist circumferences per 5 cm Waist to hip ratio per 0.1 unit 
Diffuse Large Beta Cell Lymphoma 
 
       
All studies 5 694 1.06 (0.97-1.15) 0% 0.92 7 967 1.12 (1.01-1.26) 0% 0.71 
Stratified by sex        
   Men 2 131 1.14 (0.90-1.44) 0% 0.67 2 131 1.33 (1.00-1.77) 0% 0.84 
   Women 4 563 1.05 (0.96-1.14) 0% 0.92 5 696 1.12 (0.98-1.27) 0% 0.91 
Stratified by geographic location 
   Europe 1 133 1.16 (0.82-1.65)   1 133 1.02 (0.69-1.50)   
North America 4 561 1.05 (0.97-1.14) 0% 0.89 6 834 1.13 (1.01-1.27) 0% 0.62 
   Asia           
           
Follicular Lymphoma 
 
       
All studies 5 956 1.00 (0.92-1.09)   7 757 0.98 (0.86-1.11) 0% 0.84 
Stratified by sex        
   Men 2 509 1.00 (0.76-1.32) 2% 0.31 2 101 0.95 (0.64-1.41) 0% 0.80 
   Women 4 447 1.00 (0.91-1.10) 0% 0.81 5 539 0.96 (0.83-1.11) 0% 0.76 
Stratified by geographic location 
   Europe 1 532 0.86 (0.60-1.24)   1 124 0.87 (0.58-1.30)   
North America 4 424 1.01 (0.92-1.11) 0% 0.80 6 633 0.99 (0.87-1.14) 0% 0.80 
25 
 
   Asia           
           
MM           
All studies 3 314 1.01 (0.97-1.05) 79.8% <0.001      
Mortality 
 
BMI per 5 kg/m² 
Non-Hodgkin’s Lymphoma 
 
       
All studies 6 3 570 1.15 (1.10-1.20) 0% 0.44      
Stratified by 
sex 
          
   Men 4 1 574 1.21 (0.94-1.56) 50% 0.11      
   Women 4 1 856 1.06 (0.91-1.24) 66% 0.03      
Stratified by geographic location 
   Europe 1 726 1.07 (0.96-1.20)        
   North 
America 
2 2 513 1.16 (1.11-1.22) 0% 0.46      
   Asia 3 331 1.18 (0.94-1.50) 22% 0.28      
           
Multiple Myeloma 
 
       
All studies 57 >2000 1.16 (1.07-1.25) 20% 0.27      
Stratified by sex      
   Men 15 903 1.12 (1.01-1.23) 0% 0.51      
   Women 21 1 039 1.13 (1.01-1.28) 38.5% 0.16      
Stratified by geographic location 
   Europe 1 284 1.25 (1.07-1.45)        
   North 
America 
3 678 1.09 (1.01-1.19) 0% 0.39      
   Asia 32 96 1.40 (0.81-2.42) 42% 0.19      
           
Leukaemia 
 
          
All studies 46 3 403 1.17 (1.05-1.30) 48.5% 0.06      
Stratified by 
sex 
          
   Men 44 1 899 1.17 (1.01-1.36) 37.5% 0.16      
26 
 
   Women 40  1 493 1.13 (0.99-1.29) 55.4% 0.08      
        
Stratified by geographic location     0.14      
Europe 2 536 1.06 (0.83-1.36) 54% 0.14      
North America 3 2 621 1.21 (0.90-1.61) 74% 0.02      
   Asia 33 164 1.35 (1.01-1.80) 0% 0.81      
           
27 
 
 
Figure 1. Flowchart of study selection. 
 
Figure 2. Dose–response and Non-linear meta-analysis of BMI and risk of HL cancer risk. 
RR, relative risk; 95% CI, 95% confidence interval. Summary RR calculated by using a 
random-effects model.  
 
Figure 3.  Dose–response meta-analysis of BMI and risk of NHL cancer risk. RR, relative 
risk; 95% CI, 95% confidence interval. Summary RR calculated by using a random-effects 
model. 
 
Figure 4.  Dose–response meta-analysis of BMI and risk of Multiple Myeloma cancer risk. 
RR, relative risk; 95% CI, 95% confidence interval. Summary RR calculated by using a 
random-effects model. 
 
Figure 5. Dose–response meta-analysis of BMI and risk of Leukaemia, AML, CLL and CML 
cancers risk. RR, relative risk; 95% CI, 95% confidence interval. Summary RR calculated by 
using a random-effects model. 
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